Valeant and its now-outgoing chief executive Michael Pearson pursued quick, aggressive price increases on acquired drugs in recent years—a strategy that is evident in documents collected during a Senate investigation.
from WSJ.com: US Business http://ift.tt/26IRHLi
via IFTTT
No comments:
Post a Comment